Used in clinical research for the treatment of hematological malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It functions as a selective inhibitor of histone deacetylase (HDAC), particularly HDAC1, HDAC2, and HDAC3, leading to increased histone acetylation, altered gene expression, and induction of tumor cell differentiation, cell cycle arrest, and apoptosis. Its oral bioavailability allows for convenient dosing in outpatient settings. Demonstrates potential in combination therapies with hypomethylating agents like azacitidine or decitabine to enhance anti-tumor effects. Also under investigation for solid tumors and other epigenetically driven cancers. Shows a favorable safety profile with manageable side effects such as fatigue, gastrointestinal disturbances, and thrombocytopenia.